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Comparison of the efficacy of brolucizumab with natural disease progression 
in wet AMD using clinical data from the Phase III HAWK and HARRIER 
trials and modelled placebo data 
Aim: To compare the treatment effect of brolucizumab, a novel anti-vascular endothelial 
growth factor therapeutic, with a putative placebo in patients with wet age-related macular 
degeneration. 
Materials and Methods: Clinical treatment-effect data from patients receiving 
brolucizumab 6 mg in the HAWK and HARRIER studies were compared with modelled 
placebo data using a previously developed and validated indirect response, non-linear, 
mixed effects model describing the natural visual acuity decline in wet age-related macular 
degeneration. The placebo model incorporated patient-level data from the sham injection 
arms of the MARINA and PIER studies, corrected for baseline best corrected visual acuity 
and age difference between these studies and the HAWK and HARRIER studies.  
Results: Compared with a modelled placebo, brolucizumab treatment was associated with 
an overall best corrected visual acuity gain of approximately 22 Early Treatment Diabetic 
Retinopathy Study letters at Week 48 and 28 letters at Week 96. 
Conclusions: As anti-vascular endothelial growth factor therapy is now a standard of care 
for wet age-related macular degeneration, it is not feasible to conduct placebo-controlled 
trials for new wet age-related macular degeneration treatments. By allowing comparison 
with the natural decline in visual acuity without treatment, this analysis conveys the 
clinical importance of brolucizumab for the treatment of wet age-related macular 
degeneration. 
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Age-related macular degeneration (AMD) is a leading cause of vision loss globally, with a 
prevalence of 8.7% 1,2. Although accounting for ~10% of AMD cases, wet AMD (wAMD; also 
known as neovascular AMD) was responsible for ~90% of AMD-associated vision loss before 
the advent of therapy in the 1980s 3,4. Initial thermal laser treatment was only effective in 
preventing wAMD-associated vision loss in a small number of cases, however, and often 
resulted in retinal scarring and recurrent neovascularisation 5,6. From the late 1990s, 
photodynamic therapy was shown to slow progression of vision loss, although the majority of 
patients did not experience improvements in best corrected visual acuity (BCVA) 7. 
The introduction of anti-vascular endothelial growth factor (VEGF) therapy in wAMD 
substantially improved patient outcomes. Pivotal trials showed that intravitreal anti-VEGF 
therapy significantly improves BCVA, with >16 Early Treatment Diabetic Retinopathy Study 
(ETDRS) letters difference versus placebo after a year of treatment 8,9. Following the approval of 
anti-VEGF therapies, such as ranibizumab, in the mid-2000s the rate of incident blindness and 
vision loss associated with wAMD reduced substantially 10. Another anti-VEGF molecule, 
aflibercept, was subsequently approved for wAMD treatment in 2011 in the US and 2012 in the 
EU. With anti-VEGF therapy having become the gold standard for wAMD treatment, approval 
was based on demonstrating non-inferiority to ranibizumab in pivotal studies 11. 
On October 7th 2019, a new generation anti-VEGF molecule, brolucizumab, was approved by the 
FDA, and has also been submitted for marketing authorization to the EMA and licencing bodies 
in several other countries and regions. Brolucizumab has a high affinity for VEGF and will be 
the first humanized single-chain antibody fragment for ophthalmic use 12. Its low molecular 
weight and size allows for more drug per dose and the potential for rapid and more effective 
tissue penetration compared with other anti-VEGF molecules 12–14. Clinically, the efficacy of 
brolucizumab in wAMD was confirmed in the Phase III HAWK and HARRIER studies, which 
demonstrated non-inferiority of brolucizumab to aflibercept in BCVA while showing superior 
anatomical results; this was achieved with >50% of patients on a 12-weekly regimen directly 
after loading 15. 
As anti-VEGF therapy is now a standard of care in wAMD, a non-inferiority approach is 
necessary when evaluating new treatments and placebo-controlled studies are not considered 
feasible for ethical reasons. However, due to the lack of a placebo-controlled trial, the clinical 
value of this new anti-VEGF therapy relative to the natural disease course of wAMD may be 
underappreciated in the ophthalmology community. Therefore in this study, we have used a 
previously developed model of natural disease progression in wAMD to compare treatment 











Materials and Methods 
Clinical data 
In the Phase III HAWK and HARRIER trials, eligible patients were aged ≥50 years and had 
untreated, active choroidal neovascular lesions secondary to AMD affecting the central subfield 
of the study eye as assessed by fluorescein angiography 15. A BCVA between 78 and 23 letters, 
inclusive, in the study eye at screening and baseline using ETDRS testing were prerequisit for 
study inclusion, respectively. Patients received a brolucizumab injection at Weeks 0, 4, and 8 
(loading phase) and thereafter every 12 weeks (q12w) but were interval adjusted to every 8 
weeks (q8w) if disease activity was present 15. In this study, patient-level data on the treatment 
effect of brolucizumab 6 mg on BCVA from both HAWK and HARRIER through to Week 96 
15,16 were compared with modelled data from untreated wAMD patients. 
Modelled data 
An empirical Bayesian indirect response, non-linear, mixed effects model of natural disease 
progression in wAMD and treatment effect in anti-VEGF treatment-naïve patients was 
previously developed using data from the ranibizumab Phase III ANCHOR, MARINA, PIER, 
and EXCITE studies 8,9,17–19. Patient-level data from 298 patients from the sham arms of the 
MARINA 9 and PIER 18 studies were used to describe the natural decrease in BCVA with 
placebo. In this model, BCVA score was treated as non-stationary at baseline and decreased to 
steady state (kin/kout) at the BCVA deterioration rate constant (kout) without treatment 
17. BCVA 
at baseline influenced the rate of BCVA change over time and patient age influenced this rate 
through its correlation with baseline BCVA. No other covariates were identified that affected the 
BCVA time profile in sham treated patients 17. The model was validated by comparing real 
outcomes with modelled outcomes using data from the HARBOR trial 20, which was not used for 
model development 17. 
The putative placebo arm was simulated using the specific covariates of baseline BCVA and age 
of patients from the brolucizumab 6 mg arms of the HAWK and HARRIER studies. The 
posterior distributions of the population parameters were used to sample the same number of 
subjects as the treated arms for both studies. Simulations were performed using RStan software 
version 2.17.3 (Stan Development Team, www.mc-stan.org).   
Results 
In the brolucizumab 6 mg arms in the HAWK (N=360) and HARRIER (N=370) studies, mean 
age at baseline was 76.7 and 74.8 years, respectively 15. Mean baseline BCVA was 60.8 
(HAWK) and 61.5 (HARRIER) ETDRS letters, and approximately 75% of study eyes had 











In our study, brolucizumab treatment was associated with a BCVA gain of ~22 ETDRS letters at 
Week 48 and ~28 letters at Week 96 versus simulated sham injection for both the HAWK and 
HARRIER studies (Figure 1 and Table 1). 
Discussion 
Pivotal trials validated anti-VEGF-A therapy for wAMD with monthly treatment, showing 
greatly improved patient outcomes. However, the need for frequent clinic and injection visits 
coupled with the anticipated increased prevalence of patients with wAMD may lead to a clinical 
scenario that is difficult to sustain. The HAWK and HARRIER studies successfully evaluated an 
alternative treatment option, and demonstrated robust BCVA gains with brolucizumab dosed 
with a q12w or q8w regimen. As these trials had a non-inferiority design, it is difficult to assess 
the impact of this new therapeutic relative to natural disease progression in wAMD. 
In this comparison with a putative placebo group, brolucizumab 6 mg consistently showed 
BCVA gains, with approximately 28 ETDRS letters difference after 96 weeks of treatment for 
both the HAWK and HARRIER trials. This corresponds to the difference between mild–
moderate visual impairment with near-normal reading ability and severe visual impairment with 
the requirement for high-power magnifiers and restricted field of vision 21. In the absence of 
treatment, the same model describes a gradual decrease in BCVA across the patient population 
(although individual drops can be sudden) to a steady state of 11 ETDRS letters 17 (the 
International Council of Ophthalmology defines near-blindness as ≤10 ETDRS letters 21). These 
data speak to the value of anti-VEGF therapy in wAMD. 
It is not possible to directly compare treatment effect data for brolucizumab in the HAWK and 
HARRIER studies with placebo data from the MARINA and PIER studies due to differences in 
patient populations. Baseline BCVA in the sham arms of the MARINA and PIER studies was 6–
7 ETDRS letters lower than in HAWK and HARRIER and patients were 2–3 years older 9,15,18. 
Baseline BCVA, and to a lesser extent age, was shown to impact BCVA change over time under 
both treatment and placebo conditions. During model development it was determined that gender 
did not affect BCVA over time. Furthermore the status of choroidal neovascularization (CNV) 
type and baseline BCVA were confounded, and including CNV type into model did not improve 
it. Based on these aspects, differences in BCVA and age between studies were corrected for in 
the model used 17. Furthermore, this model has been shown to hold true over the complete range 
of BCVA scores 17. 
The model provides a unique opportunity to demonstrate BCVA score behaviour under natural 
disease progression. Its accuracy in describing natural disease progression and treatment effect in 
anti-VEGF treatment-naïve patients has been shown through external validation using data from 
the HARBOR study. In that study, modelled data was shown to correlate well with actual data 
for ranibizumab, including prediction of a 2 mg ranibizumab dose that was not used for model 
development 17,20. An earlier version of the model, using 1-year data from the same studies, 
supported a label update approval by the EMA for individualised visual acuity-guided treatment 











Limitations of the study include the relatively low number of placebo patients informing the 
model, totalling 298 patients from two studies 17. In addition, unknown covariates that were not 
identified during model development, and therefore not used in simulations to adjust for 
differences in the HAWK and HARRIER populations, could influence the BCVA time profile in 
untreated patients. 
Given the success of anti-VEGF therapies in wAMD, it is easy to forget the debilitating effects 
of this disease, where vision loss is almost guaranteed without treatment. In this study, 
brolucizumab provided vision gains of ~22 letters at Week 48 and ~28 letters at Week 96 versus 
natural (untreated) visual acuity decline in cohorts with mean baseline BCVA below 71 ETDRS 
letters. Furthermore, in HAWK and HARRIER, gains with brolucizumab treatment were 
achieved with >50% of patients on a 12-weekly retreatment regimen, commenced immediately 
after loading. Our analysis enables better understanding of the clinical value of this new-
generation intravitreal anti-VEGF treatment for wAMD. Future research will focus on 
understanding the utility of this new molecule in other anti-VEGF responsive indications.  
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Table 1. Mean observed BCVA. BCVA = best corrected visual acuity; ETDRS = Early 
Treatment Diabetic Retinopathy Study; SE = standard error 
 






HARRIER 48 352 69.2 (0.8) 46.5 (1.1) 22.7 (1.4) 
HAWK 48 326 68.1 (1.0) 45.9 (1.1) 22.1 (1.5) 
HARRIER 96 342 68.7 (0.9) 41.1 (1.3) 27.6 (1.5) 














Figure 1.  Mean BCVA in the HARRIER (n=352 at 48 weeks and n=342 at 96 weeks) and HAWK (n=326 
at 48 weeks and n=304 at 96 weeks) studies versus putative placebo. In HAWK and HARRIER, patients 
received brolucizumab 3 mg/6 mg at Weeks 0, 4, and 8 (loading phase) and thereafter every 12 weeks 
but were interval adjusted to every 8 weeks if disease activity was present. Solid lines show brolucizumab 
6 mg treatment effect, dashed lines show modelled natural disease progression. Shaded areas show 
95% confidence intervals. BCVA = best corrected visual acuity 
 
 
